1 / 24

Disinformation from Press Releases? Peter Steele Current Patents Ltd London W1T 4LB peter@current-patents.com www.curren

Disinformation from Press Releases? Peter Steele Current Patents Ltd London W1T 4LB peter@current-patents.com www.current-patents .com. Current Patents Ltd - ACS, San Diego, April 2001. Background. 10,000 pharma/biotech press releases analysed each year for Investigational Drugs database (IDdb)

layne
Download Presentation

Disinformation from Press Releases? Peter Steele Current Patents Ltd London W1T 4LB peter@current-patents.com www.curren

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Disinformation from Press Releases?Peter SteeleCurrent Patents LtdLondon W1T 4LBpeter@current-patents.comwww.current-patents .com Current Patents Ltd - ACS, San Diego, April 2001

  2. Background 10,000 pharma/biotech press releases analysedeach year for Investigational Drugs database (IDdb) 10% with IP implications - four per day Analysis for technical intelligence by skilled analysts Current Patents Ltd - ACS, San Diego, April 2001

  3. Grey Literature Formal Journals Patents Technical Reports Meetings Grey Advertisements Newspapers Brochures Broadcasts Analysts’ Briefings Annual Reports Press releases Current Patents Ltd - ACS, San Diego, April 2001

  4. Grey Literature Grey Patents Advertisements Newspapers Brochures Broadcasts Analysts’ Briefings Annual Reports Press releases Formal Journals (Patents) Technical Reports Meetings Current Patents Ltd - ACS, San Diego, April 2001

  5. Intelligence = Effort Press ReleasesDOLPHIN(Database of All Pharmaceutical Inventions) One analyst – 3 to 4 days/week Current Patents Ltd - ACS, San Diego, April 2001

  6. Sources - general (1) • PR Newswire • Business Newswire • Canada Newswire • Medical, Hospital and Biotech sections • Direct email from companies Current Patents Ltd - ACS, San Diego, April 2001

  7. Sources - general (2) • CAS Chemical industry newswww.cas.org/reuters/chemnews.html • Daily industry news, individually profiledwww.office.com Current Patents Ltd - ACS, San Diego, April 2001

  8. Sources - general (3) • Pharmaceutical News & Informationwww.coreynahman.com • Pharmalicensingwww.pharmalicensing.com • Hoover’s Onlinewww.hoovershbn.hoovers.com • Bioresearch Onlinewww.news.bioresearchonline.com Current Patents Ltd - ACS, San Diego, April 2001

  9. Sources - Patent • USPTO Official Gazettewww.uspto.gov/web/offices/com/sol/og • UK Official Journalwww.patent.gov.uk/patent/notices • Australian PO Decisionswww.austlii.edu.au/au/cases/cth/APO • UK Court Judgementswww.wood.ccta.gov.uk/courtser/judgements.nsf Current Patents Ltd - ACS, San Diego, April 2001

  10. Country of Origin US 235 UK 17 Canada 16 Germany 8 Switzerland 7 Others (NL,FR,IL,JP DK,SE,AT) 17 Current Patents Ltd - ACS, San Diego, April 2001

  11. State of Origin CA 97 NJ 30 MA 28 WA 14 PA 10 NY 9 MD 8 Others (16) 40 Current Patents Ltd - ACS, San Diego, April 2001

  12. Multinationals’ PRs Issuing Party – 30/300 (10%) Second Party – 68/300 (23%) Non-Government – 68/200 (34%) Current Patents Ltd - ACS, San Diego, April 2001

  13. Three or more PRs issued Incyte Maxygen Myriad SciClone Viragen Vivus XTL Abgenix, Antex Ariad Arqule Coulter Genzyme Current Patents Ltd - ACS, San Diego, April 2001

  14. Partnerships in Press Releases First (issuing) party with Second Party etc 67% Company with Company/Institution 33% Company with Government Agency 22% USPTO 11% FDA Current Patents Ltd - ACS, San Diego, April 2001

  15. Technology Types 65% Fundamental (“platform”) 35% Product Oriented (69) Preclinical (21) Phase I (16) Phase II (12) Phase III (6) Marketed (14) Current Patents Ltd - ACS, San Diego, April 2001

  16. Details to Cite Patent Number - get it right!!! Inventor Names Date and country of origin Identity of Originator – other interests? Name of Product/Technology Current Patents Ltd - ACS, San Diego, April 2001

  17. Case Study (1): Immutech “…….announced today it had been issued US Patent No 6172104B1entitled “Dicationic dibenzofuran……..” March 26,2001 • Actually issued January 9, 2001 • Assignee is University of North Carolina • US Government (NIH) retains interest • Originates from joint program with Georgia, Duke &Auburn universities Current Patents Ltd - ACS, San Diego, April 2001

  18. Case Study (2): “Interleukin Genetics… ….announced today that it was awarded Patent No 6210877 for the discovery that certain IL-1 gene variations…receiveda Notice of Allowance in June 2000” March 29, 2001 US6210877 was not published until April 3, 2001 Published previously as PCT (WO9840517, Sept 1998) June 2000 announcement referring to PCT wouldhave been more helpful! Current Patents Ltd - ACS, San Diego, April 2001

  19. Case Study (3): Roche….. …receives EU approval for Herceptin…..discovered anddeveloped by Genentech…… Aug 30, 2000 Protein Design Labs and the US Army hold fundamentalpatents covering many humanized antibodies Genentech is a non-exclusive licensee of PDL Current Patents Ltd - ACS, San Diego, April 2001

  20. Case Study (4): Abbott… …and Triangle Pharma….results of phase I/II trial in which DAPD…UNC investigators conducting study…. DAPD claimed by Emory University in 1992 Emory has interference & opposition actions with BioChem Pharma Current Patents Ltd - ACS, San Diego, April 2001

  21. Press Releases: Conclusions Take nothing for granted Expect contradictions Expect old information Expect wrong numbers/dates……… Current Patents Ltd - ACS, San Diego, April 2001

  22. “At best, a good press release can be an excellent source of technical intelligence – but that applies to only 10-20% of examples……” Current Patents Ltd - ACS, San Diego, April 2001

  23. “….at worst there can be a lot of skilled effort required to extract and codify that intelligence, and sometimes there is nothing of substance to be said.” Current Patents Ltd - ACS, San Diego, April 2001

  24. Disinformation from Press Releases?Yes, if you’re not careful!Peter SteeleCurrent Patents Ltd, Londonpeter@current-patents.comwww.current-patents .com Current Patents Ltd - ACS, San Diego, April 2001

More Related